Targeting the Wnt/beta-catenin pathway in renal cell carcinoma

Anticancer Research

Volumn 34, Issue 8, 2014, Pages 4101-4108

  Von Schulz Hausmann, Sarah Annette ^a   Schmeel, Leonard Christopher ^a   Schmeel, Frederic Carsten ^a   Schmidt Wolf, Ingo G H ^a  

^a Cologne Excellence Cluster on Cellular Stress Responses in Aging Associated Diseases   (Germany)

Author keywords

Beta catenin; Renal cancer; Signaling therapies; Wnt inhibitors; Wnt pathway

Indexed keywords

3,3' DIHEXYLOXACARBOCYANINE; BETA CATENIN; CICLOPIROXOLAMINE; ETACRYNIC ACID; PIROCTONE ETHANOLAMINE; PROPIDIUM IODIDE; WNT PROTEIN; CICLOPIROX; CTNNB1 PROTEIN, HUMAN; ETHANOLAMINE DERIVATIVE; PYRIDONE DERIVATIVE;

APOPTOSIS; ARTICLE; CANCER CELL; CARCINOGENESIS; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; FIBROBLAST; FLOW CYTOMETRY; HUMAN; HUMAN CELL; KIDNEY CARCINOMA; PERIPHERAL LYMPHOCYTE; PROTEIN EXPRESSION; PROTEIN TARGETING; WNT SIGNALING PATHWAY; BETA-CATENIN; DRUG ANTAGONISM; DRUG COMBINATION; DRUG EFFECT; KIDNEY CANCER; KIDNEY TUMOR; PATHOLOGY; PHYSIOLOGY; SIGNALING THERAPIES; TUMOR CELL LINE; WNT INHIBITORS;

BETA-CATENIN; RENAL CANCER; SIGNALING THERAPIES; WNT INHIBITORS; WNT PATHWAY;

BETA CATENIN; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; CELL SURVIVAL; DRUG COMBINATIONS; ETHACRYNIC ACID; ETHANOLAMINES; HUMANS; KIDNEY NEOPLASMS; PYRIDONES; WNT SIGNALING PATHWAY;

EID: 84908604669     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Siegel R, Naishadham D and Jemal A: Cancer statistics, 2012. CA Cancer J Clin 62: 10-29, 2012.
2. Weiss RH and Lin PY: Kidney cancer: identification of novel targets for therapy. Kidney Int 69: 224-232, 2006.
3. Feldstein MS, Rhodes DJ, Parker AS, Orford RR and Castle EP: The haphazard approach to the early detection of asymptomatic renal cancer: results from a contemporary executive health programme. BJU Int 104: 53-56, 2009.
4. Flanigan RC, Salmon SE, Blumenstein BA, Bearman SI, Roy V, McGrath PC, Caton JR Jr., Munshi N and Crawford ED: Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 345: 1655-1659, 2001.
5. Pulkkinen K, Murugan S and Vainio S: Wnt signaling in kidney development and disease. Oncogenesis 4: 2, 55-59, 2008.
6. Nusse R. Wnt signaling in disease and in development. Cell Res 15: 28-32, 2005.
7. Polakis P: Wnt signaling and cancer. Genes Dev 14: 1837-1851, 2000.
8. Aberle H, Bauer A, Stappert J, Kispert A and Kemler R: beta-catenin is a target for the ubiquitin-proteasome pathway. EMBO J 16(13): 3797-3804, 1997.
9. Willert K and Jones KA: Wnt signaling: is the party in the nucleus? Genes Dev 20: 1394-1404, 2006.
10. Kim Y, Schmidt M, Endo T, Lu D, Carson D and Schmidt-Wolf IG: Targeting the Wnt/beta-catenin pathway with the antifungal agent ciclopirox olamine in a murine myeloma model. In Vivo 25(6): 887-893, 2011.
11. Schmeel LC, Schmeel FC, Kim Y, Endo T, Lu D and Schmidt-Wolf IG: Targeting the Wnt/beta-catenin pathway in multiple myeloma. Anticancer Res 33(11): 4719-4726, 2013.
12. Schmidt M, Sievers E, Endo T, Lu D, Carson D and Schmidt-Wolf IG: Targeting Wnt pathway in lymphoma and myeloma cells. Br J Haematol 144(5): 796-808, 2009.
13. Kim Y, Alpmann P, Blaum-Feder S, Krämer S, Endo T, Lu D, Carson D and Schmidt-Wolf IG: Increased in vivo efficacy of lenalidomide by addition of piroctone olamine. In Vivo 25(1): 99-103, 2011.
14. Schmeel FC, Schmeel LC, Kim Y and Schmidt-Wolf IG: Piceatannol exhibits selective toxicity to multiple myeloma cells and influences the Wnt/ beta-catenin pathway. Hematol Oncol 2014; doi: 10.1002/hon.2122
15. Koller CM, Kim Y and Schmidt-Wolf IG. Targeting renal cancer with a combination of WNT inhibitors and a bi-functional peptide. Anticancer Res 33(6): 2435-2440, 2013.
16. Banumathy G and Cairns P: Signaling pathways in renal cell carcinoma. Cancer Biol Ther 10(7): 658-664, 2010
17. Saini S, Majid S and Dahiya R: The complex roles of Wnt antagonists in RCC. Nat Rev Urol 8(12): 690-699, 2011.
18. Guillén-Ahlers H: Wnt signaling in renal cancer. Curr Drug Targets 9(7): 591-600, 2008.
19. Kruck S, Eyrich C, Scharpf M, Sievert KD, Fend F, Stenzl A and Bedke J: Impact of an Altered Wnt1/innodatabeta-Catenin Expression on Clinicopathology and Prognosis in Clear Cell Renal Cell Carcinoma. Int J Mol Sci 14(6): 10944-10957, 2013.
20. Schmidt M, Kim Y, Gast SM, Endo T, Lu D, Carson D and Schmidt-Wolf IG: Increased in vivo efficacy of lenalidomide and thalidomide by addition of ethacrynic acid. In Vivo 25(3): 325-333, 2011.
21. Lu D, Liu JX, Endo T, Zhou H, Yao S, Willert K, Schmidt-Wolf IG, Kipps TJ and Carson DA: Ethacrynic acid exhibits selective toxicity to chronic lymphocytic leukemia cells by inhibition of the Wnt/beta-catenin pathway. PLoS One 4(12): e8294, 2009.
22. Kim Y, Gast SM, Endo T, Lu D, Carson D and Schmidt-Wolf IG: In vivo efficacy of the diuretic agent ethacrynic acid against multiple myeloma. Leuk Res 36(5): 598-600, 2012.
23. Aizawa S, Ookawa K, Kudo T, Asano J, Hayakari M and Tsuchida S: Characterization of cell death induced by ethacrynic acid in a human colon cancer cell line DLD-1 and suppression by N-acetyl-L-cysteine. Cancer Sci 94(10): 886-893, 2003.
24. Han Y, Englert JA, Delude RL and Fink MP: Ethacrynic acid inhibits multiple steps in the NF-kappaB signaling pathway. Shock 23(1): 45-53, 2005.
25. Belenky P, Camacho D and Collins JJ: Fungicidal drugs induce a common oxidative-damage cellular death pathway. Cell Rep 3(2): 350-358, 2013.
26. Eberhard Y, McDermott SP, Wang X, Gronda M, Venugopal A, Wood TE, Hurren R, Datti A, Batey RA, Wrana J, Antholine WE, Dick JE and Schimmer AD: Chelation of intracellular iron with the antifungal agent ciclopirox olamine induces cell death in leukemia and myeloma cells. Blood 114(14): 3064-3073, 2009.
27. Zhou H, Shen T, Luo Y, Liu L, Chen W, Xu B, Han X, Pang J, Rivera CA and Huang S: The antitumor activity of the fungicide ciclopirox. Int J Cancer 127(10): 2467-2477, 2010.
28. Song S, Christova T, Perusini S, Alizadeh S, Bao RY, Miller BW, Hurren R, Jitkova Y, Gronda M, Isaac M, Joseph B, Subramaniam R, Aman A, Chau A, Hogge DE, Weir SJ, Kasper J, Schimmer AD, Al-awar R, Wrana JL and Attisano L: Wnt inhibitor screen reveals iron dependence of innodatabeta-catenin signaling in cancers. Cancer Res 71(24): 7628-7639, 2011.
29. Coombs GS, Schmitt AA, Canning CA, Alok A, Low IC, Banerjee N, Kaur S, Utomo V, Jones CM, Pervaiz S, Toone EJ and Virshup DM: Modulation of Wnt/innodatabeta-catenin signaling and proliferation by a ferrous iron chelator with therapeutic efficacy in genetically engineered mouse models of cancer. Oncogene 31(2): 213-225, 2012.
30. Dubini F, Bellotti MG, Frangi A, Monti D and Saccomani L: In vitro antimycotic activity and nail permeation models of a piroctone olamine (octopirox) containing transungual water soluble technology. Arzneimittelforschung 55(8): 478-483, 2005.
31. Marks R, Dykes PJ, Hill S, Pearse AD and Futterer E: Effects of anti-dandruff agents on epidermal behaviour, Joint Conference ISSCC/GKC, Munich, pp. 11-18, 1987.